A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma.
NCT02149199 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 3850
Last updated 2019-11-15
Summary
The purpose of this study is to test if Symbicort® (budesonide/formoterol) Turbuhaler® is effective in treating asthma when used 'as needed' in patients with milder asthma. The efficacy of Symbicort® 'as needed' will be compared with: 1) terbutaline Turbuhaler® 'as needed' and with 2) Pulmicort (budesonide) Turbuhaler® twice daily plus terbutaline Turbuhaler® 'as needed'.
Conditions
Interventions
- DRUG
-
budesonide/formoterol 'as needed' + budesonide placebo bid
Symbicort (budesonide/ formoterol) 160/4.5 μg powder for inhalation 'as needed' plus Pulmicort placebo 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening), 52-week treatment
- DRUG
-
terbutaline 'as needed' + placebo budesonide bid
Terbutaline 0.4 mg powder for inhalation 'as needed' plus placebo Pulmicort (budesonide) 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening), 52-week treatment
- DRUG
-
budesonide bid + terbutaline 'as needed'
Pulmicort (budesonide) 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening) plus terbutaline 0.4 mg powder for inhalation 'as needed', 52-week treatment
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Paul M O'Byrne, MB, FRCP(C), FRSC · McMaster University, Hamilton, Canada
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- TRIPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 12 Years
- Max Age
- 130 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2014-07-07
- Primary Completion
- 2017-08-02
- Completion
- 2017-08-02
Countries
- Australia
- Brazil
- Bulgaria
- Canada
- Chile
- China
- Hungary
- Mexico
- Peru
- Philippines
- Poland
- Romania
- Russia
- South Africa
- South Korea
- Ukraine
- United Kingdom
- Vietnam
Study Locations
More Related Trials
-
Safety & Efficacy of Symbicort® Turbuhaler® (1, 2, and 4 x 160/4.5 µg Twice Daily) in Japanese Patients With Asthma
NCT00255255 ·Status: COMPLETED ·Phase: PHASE3
-
Comparing Symbicort® As-Needed or Bricanyl As-Needed or Pulmicort® Once Daily + Bricanyl As-Needed in Asthma Patients
NCT00989833 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluating the Symbicort Turbuhaler (Formoterol/Budesonide) Maintenance and Reliever Therapy for Asthma in Daily Practice
NCT00782314 ·Status: COMPLETED
-
Prevention of Asthma Relapse After Discharge From Emergency
NCT00326053 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Investigate the Efficacy of Symbicort® SMART.
NCT00839800 ·Status: COMPLETED ·Phase: PHASE3
-
Symbicort Single Inhaler Therapy vs Conventional Best Practice for the Treatment of Persistent Asthma in Adults
NCT00385593 ·Status: TERMINATED ·Phase: PHASE3
-
Randomized, Placebo-Controlled, Multidose, Study Comparing Generic Budesonide/Formoterol Fumarate Dihydrate to Symbicort® in Asthmatic Participants
NCT02495168 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Budesonide / Formoterol Combination in Repeated AMP Provocations
NCT00272753 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy of Symbicort pMDI Administered Once Daily in Adolescents and Adults During 12 Weeks - STEM
NCT00652392 ·Status: COMPLETED ·Phase: PHASE3
-
A 12-Week Study in Asthmatic Children Ages 6 to <12 Years, Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 μg and Symbicort pMDI 80/4.5 μg, Compared With Budesonide pMDI 80 μg
NCT02091986 ·Status: COMPLETED ·Phase: PHASE3
-
Titratable Dosing in Moderate to Severe Asthmatics
NCT00651768 ·Status: COMPLETED ·Phase: PHASE3
-
STYLE - Symbicort Single Inhaler Therapy vs Conventional Therapy in Treatment of Persistent Asthma
NCT00252824 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Preventive Treatment With Symbicort or Budicort Turbohaler in Childhood Asthma Return to School Epidemic
NCT01179152 ·Status: UNKNOWN ·Phase: NA
-
Relative Bronchodilating Effects of Formoterol When Administered Via Symbicort Pressurized Metered-dose Inhaler (pMDI) or Oxis Turbuhaler
NCT00658255 ·Status: COMPLETED ·Phase: PHASE2
-
Use of Symbicort or Pulmicort to Treat Viral-mediated Asthma Exacerbations
NCT01218399 ·Status: COMPLETED ·Phase: NA
-
Randomized, Placebo-controlled, Multi-dose, Study Comparing Budesonide/Formoterol to Symbicort® in Asthmatic Patients
NCT03015259 ·Status: COMPLETED ·Phase: PHASE3
-
Symbicort Single Inhaler Therapy for Asthma in a General Practice Setting
NCT00235911 ·Status: COMPLETED ·Phase: PHASE3
-
A Non-inferiority Study to Evaluate Efficacy, Safety and Tolerability of NEUMOTEROL® 400 and SYMBICORT® Forte in Adults With Asthma
NCT02233803 ·Status: COMPLETED ·Phase: PHASE4
-
New Breath Actuated MDI Symbicort Compared to Symbicort pMDI and Budesonide pMDI for 12 Weeks Twice a Day
NCT01360021 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Investigate the Safety and Efficacy of High Dose of Symbicort® SMART in Japanese Patients
NCT00837967 ·Status: COMPLETED ·Phase: PHASE3
-
Bioequivalence Study of Budesonide/Formoterol Easyhaler and Symbicort Turbohaler in Asthmatics
NCT00964535 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Pharmacokinetic Study on Budesonide/Formoterol Device-metered Dry Powder Inhalers
NCT01668121 ·Status: COMPLETED ·Phase: PHASE1
-
Gemini Symbicort pMDI
NCT00646516 ·Status: COMPLETED ·Phase: PHASE3
-
Symbicort Onset of Action 2
NCT00646009 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy of Symbicort Versus Its Monocomponents - SPRUCE 160/4.5
NCT00652002 ·Status: COMPLETED ·Phase: PHASE3